Want to see SE:ENZY full AI Analyst Report?

Enzymatica AB (ENZY) Price & Analysis

0 Followers

ENZY Stock Chart & Stats

kr2.00

-kr0.34(-10.43%)

At close: Mar 06 4:00 PM EST

kr2.00

-kr0.34(-10.43%)

Day’s Range― - ―

52-Week Rangekr1.60 - kr3.40

Previous CloseN/A

Volume634.97K

Average Volume (3M)76.42K

Market Cap

kr451.49M

Enterprise Valuekr583.59

Total Cash (Recent Filing)kr13.14M

Total Debt (Recent Filing)kr14.17M

Price to Earnings (P/E)―

Beta-0.12

Next Earnings

Oct 29, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.19

Shares Outstanding242,735,100

10 Day Avg. Volume91,849

30 Day Avg. Volume76,425

Financial Highlights & Ratios

PEG Ratio0.36

Price to Book (P/B)3.71

Price to Sales (P/S)8.56

P/FCF Ratio-11.19

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.3

Revenue Forecast (FY)kr109.00M

Bulls Say, Bears Say

Bulls Say

Very Low LeverageMinimal leverage reduces financial risk and interest burden, preserving flexibility to fund commercialization or withstand operating volatility. This balance-sheet cushion is a durable strength, although it does not offset the company’s continuing operating losses or cash consumption.

Solid Gross MarginA gross margin near 59% indicates that ColdZyme and related products generate reasonable product-level economics before operating expenses. If maintained, this margin provides a foundation for future operating leverage should sales scale or overhead become more efficient.

Multi-market Consumer Healthcare DistributionDistribution across pharmacies, retail, and online channels in multiple markets gives the company several routes to reach consumers and supports geographic commercialization. This diversified channel model can provide a platform for broader adoption beyond a single local market.

Bears Say

Persistent Deep Operating LossesDeep and persistent operating losses show that gross product economics are currently overwhelmed by operating expenses. Continued losses can erode the equity base, restrict internal funding capacity, and make the business dependent on a sustained improvement in scale or cost discipline.

Ongoing Cash BurnNegative operating and free cash flow means the business is not yet self-funding and continues to consume cash to operate. Although the outflow improved versus prior periods, persistent burn can reduce financial resilience and limit the resources available for product and market expansion.

Limited Revenue Momentum And Equity ErosionSlightly lower trailing revenue indicates limited top-line momentum at a time when the company needs greater scale to absorb its cost base. Combined with materially declining equity, this weak growth profile increases pressure on management to improve commercialization and profitability.

ENZY FAQ

What was Enzymatica AB’s price range in the past 12 months?

Enzymatica AB lowest stock price was kr1.60 and its highest was kr3.40 in the past 12 months.

What is Enzymatica AB’s market cap?

Enzymatica AB’s market cap is kr451.49M.

When is Enzymatica AB’s upcoming earnings report date?

Enzymatica AB’s upcoming earnings report date is Oct 29, 2026 which is in 39 days.

How were Enzymatica AB’s earnings last quarter?

Enzymatica AB released its earnings results on Jul 16, 2026. The company reported -kr0.053 earnings per share for the quarter.

Is Enzymatica AB overvalued?

According to Wall Street analysts Enzymatica AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Enzymatica AB pay dividends?

Enzymatica AB does not currently pay dividends.

What is Enzymatica AB’s EPS estimate?

Enzymatica AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Enzymatica AB have?

Enzymatica AB has 242,735,100 shares outstanding.

What happened to Enzymatica AB’s price movement after its last earnings report?

Enzymatica AB reported an EPS of -kr0.053 in its last earnings report. Following the earnings report the stock price went down -6.034%.

Which hedge fund is a major shareholder of Enzymatica AB?

Currently, no hedge funds are holding shares in SE:ENZY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Enzymatica AB

Enzymatica AB, a life science company headquartered in Lund, Sweden, focuses on the development and sale of medical devices for infection-related illnesses. Founded in 2007, its primary offering is the ColdZyme mouth spray, designed to help prevent and reduce the duration of the common cold. The company also produces various enzyme formulations. This mouth spray is distributed across several European markets under different brand names: ViruProtect in Denmark, STADAProtect in Germany, Psysiomer Stop Virus in France, and Zerinol Virus Defense in Italy.